ArticleInternational journal of nanomedicine2026
Intratracheal Administration of pH-Responsive Nanomicelles: A More Effective Strategy for Enhanced Intracellular Drug Delivery in Lung Cancer Treatment.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The efficacy of chemotherapy for treating lung cancer is hindered by insufficient intracellular drug utilisation. Moreover, non-targeted distribution often leads to severe side effects, resulting in poor prognosis and low patient compliance. Therefore, a more effective strategy is required to achieve effective treatment. In this study, we aimed to develop a pH-responsive nanoplatform for intratracheal administration to enhance drug accumulation in lung cancer tissues and promote the accumulation of drugs within tumour cells. Results: A self-assembled nanomicelle named SN-38@PEG-PMMSD (PPM) was constructed using a cinnamaldehyde synthetic carrier material loaded with SN-38 and nanoprecipitation. Intratracheal administration enhanced the accumulation of PPM within the lungs and tumors (the fold increase in lung accumulation following intratracheal (i.t.) were 49.63-fold higher than intravenous (i.v.) delivery at the 48-hour timepoint). Owing to its small size, PPM can easily penetrate deep into tumour tissues. The micro-acidic environment characteristic of tumours increases the efficiency of tumour cell uptake of PPM. This triggered a pH-responsive reaction in the acidic lysosomal milieu, leading to dissociation of PPM and the regeneration of cinnamaldehyde while releasing SN-38. Cinnamaldehyde acted as a reactive oxygen species (ROS) amplifier, facilitating ROS generation. Elevated ROS levels, in conjunction with SN-38, resulted in strong antitumor effects. Conclusion: In summary, Intratracheal administration of pH-responsive PPM is anticipated to enhance drug accumulation in tumour tissues, improve drug uptake by tumour cells, and achieve effective treatment of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.